

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	23	banchereau adj jacques	US-PGPUB; USPAT; DERWENT	OR	ON	2005/08/16 07:53
L3	4	palucka adj anna	US-PGPUB; USPAT; DERWENT	OR	ON	2005/08/16 07:53
L5	2	blanco adj patrick	US-PGPUB; USPAT; DERWENT	OR	ON	2005/08/16 07:53

=> d'his

(FILE 'HOME' ENTERED AT 08:51:42 ON 16 AUG 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 08:52:03 ON 16 AUG 2005

E BANCHEREAU JACQUES /AU

L1 546 S E3

E PALUCKA ANNA /AU

L2 5 S E5

L3 1 S E4

E BLANCO PARTICK /AU

L4 41 S E8

L5 18 S L1 (L) L4

L6 12 DUP REM L5 (6 DUPLICATES REMOVED)

L6 ANSWER 1 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 TI Dendritic cells: Controllers of the immune system and a new promise for
 immunotherapy.
 PY 2003
 AU **Banchereau, Jacques; Paczesny, Sophie; Blanco, Patrick**
 ; Bennett, Lynda; Pascual, Virginia; Fay, Joseph; Palucka, A. Karolina
 [Reprint Author]
 SO Chiorazzi, Nicholas [Editor, Reprint Author]; Lahita, Robert G. [Editor];
 Capra, J. Donald [Editor]; Ferrarini, Manlio [Editor]; Zabriskie, John B.
 [Editor]. (2003) pp. 180-187. Immune mechanisms and disease. print.
 Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, NY,
 10021, USA. Series: Annals of the New York Academy of Sciences.
 Meeting Info.: Conference on Immune Mechanisms and Disease. St. George's,
 Grenada, West Indies, Windward Islands. April 14-17, 2002. Henry Kunkel
 Society; New York Academy of Sciences.
 ISSN: 0077-8923 (ISSN print). ISBN: 1-57331-434-X (cloth), 1-57331-435-8
 (paper).

AU **Banchereau, Jacques; Paczesny, Sophie; Blanco, Patrick**
 ; Bennett, Lynda; Pascual, Virginia; Fay, Joseph; Palucka, A. Karolina
 [Reprint Author]

L6 ANSWER 2 OF 12 MEDLINE on STN DUPLICATE 1
 TI Dendritic cells: controllers of the immune system and a new promise for
 immunotherapy.
 PY 2003
 AU **Banchereau Jacques; Paczesny Sophie; Blanco Patrick;**
 Bennett Lynda; Pascual Virginia; Fay Joseph; Palucka A Karolina
 SO Annals of the New York Academy of Sciences, (2003 Apr) 987 180-7. Ref: 22
 Journal code: 7506858. ISSN: 0077-8923.
 AU **Banchereau Jacques; Paczesny Sophie; Blanco Patrick;**
 Bennett Lynda; Pascual Virginia; Fay Joseph; Palucka A Karolina

L6 ANSWER 3 OF 12 MEDLINE on STN DUPLICATE 2
 TI Blood dendritic cells and DC-poietins in systemic lupus erythematosus.
 PY 2002
 AU Gill Michelle A; **Blanco Patrick;** Arce Edsel; Pascual Virginia;
Banchereau Jacques; Palucka A Karolina
 SO Human immunology, (2002 Dec) 63 (12) 1172-80.
 Journal code: 8010936. ISSN: 0198-8859.
 AU Gill Michelle A; **Blanco Patrick;** Arce Edsel; Pascual Virginia;
Banchereau Jacques; Palucka A Karolina

L6 ANSWER 4 OF 12 MEDLINE on STN DUPLICATE 3
 TI The interplay of dendritic cell subsets in systemic lupus erythematosus.
 PY 2002
 AU Palucka A Karolina; **Banchereau Jacques; Blanco Patrick**
 ; Pascual Virginia
 SO Immunology and cell biology, (2002 Oct) 80 (5) 484-8. Ref: 40
 Journal code: 8706300. ISSN: 0818-9641.
 AU Palucka A Karolina; **Banchereau Jacques; Blanco Patrick**
 ; Pascual Virginia

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
 TI Introduction to dendritic cells
 PY 2002
 AU **Blanco, Patrick;** Palucka, A. Karolina; **Banchereau,**
Jacques
 SO Gene Therapy of Cancer (2nd Edition) (2002), 167-177. Editor(s): Lattime,
 Edmund C.; Gerson, Stanton L. Publisher: Academic Press, San Diego, Calif.
 CODEN: 69CXHL; ISBN: 0-12-437551-0
 AU **Blanco, Patrick;** Palucka, A. Karolina; **Banchereau,**
Jacques

L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
 TI Induction of dendritic cell differentiation by IFN- α in systemic
 lupus erythematosus
 PY 2001
 AU **Blanco, Patrick;** Palucka, A. Karolina; Gill, Michelle; Pascual,

Virginia; **Banchereau, Jacques**
SO Science (Washington, DC, United States) (2001), 294(5546), 1540-1543
CODEN: SCIEAS; ISSN: 0036-8075

AU **Blanco, Patrick**; Palucka, A. Karolina; Gill, Michelle; Pascual,
Virginia; **Banchereau, Jacques**

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
TI Cross-priming of naive CD8 T cells against melanoma antigens using
dendritic cells loaded with killed allogeneic melanoma cells
PY 2000
AU Berard, Frederic; **Blanco, Patrick**; Davoust, Jean;
Neidhart-Berard, Eve-Marie; Nouri-Shirazi, Mahyar; Taquet, Nicolas;
Rimoldi, Donata; Cerottini, Jean Charles; **Banchereau, Jacques**;
Palucka, A. Karolina
SO Journal of Experimental Medicine (2000), 192(11), 1535-1543
CODEN: JEMEAV; ISSN: 0022-1007

AU Berard, Frederic; **Blanco, Patrick**; Davoust, Jean;
Neidhart-Berard, Eve-Marie; Nouri-Shirazi, Mahyar; Taquet, Nicolas;
Rimoldi, Donata; Cerottini, Jean Charles; **Banchereau, Jacques**;
Palucka, A. Karolina

L6 ANSWER 8 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Altered B cells and dendritic cells in SLE.
PY 2000
AU Pascual, Virginia [Reprint author]; Arce, Edsel; Gill, Michelle; Jackson,
Deborah; **Blanco, Patrick**; Pulendran, Bali; Palucka, Karolina;
Banchereau, Jacques
SO FASEB Journal, (April 20, 2000) Vol. 14, No. 6, pp. A1209. print.
Meeting Info.: Joint Annual Meeting of the American Association of
Immunologists and the Clinical Immunology Society. Seattle, Washington,
USA. May 12-16, 2000.
CODEN: FAJOEC. ISSN: 0892-6638.

AU Pascual, Virginia [Reprint author]; Arce, Edsel; Gill, Michelle; Jackson,
Deborah; **Blanco, Patrick**; Pulendran, Bali; Palucka, Karolina;
Banchereau, Jacques

L6 ANSWER 9 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Dendritic cells loaded with killed allogeneic melanoma cells induce
melanoma specific immunity.
PY 2000
AU **Blanco, Patrick** [Reprint author]; Berard, Frederic [Reprint
author]; Davoust, Jean [Reprint author]; Taquet, Nicolas [Reprint author];
Rolland, Alexandre [Reprint author]; Nouri-Shirazi, Mahyar [Reprint
author]; Kraus, Elizabeth T. [Reprint author]; Rimoldi, Donata; Cerottini,
Jean Charles; **Banchereau, Jacques** [Reprint author]; Palucka,
Karolina A. [Reprint author]
SO FASEB Journal, (April 20, 2000) Vol. 14, No. 6, pp. A946. print.
Meeting Info.: Joint Annual Meeting of the American Association of
Immunologists and the Clinical Immunology Society. Seattle, Washington,
USA. May 12-16, 2000.
CODEN: FAJOEC. ISSN: 0892-6638.

AU **Blanco, Patrick** [Reprint author]; Berard, Frederic [Reprint
author]; Davoust, Jean [Reprint author]; Taquet, Nicolas [Reprint author];
Rolland, Alexandre [Reprint author]; Nouri-Shirazi, Mahyar [Reprint
author]; Kraus, Elizabeth T. [Reprint author]; Rimoldi, Donata; Cerottini,
Jean Charles; **Banchereau, Jacques** [Reprint author]; Palucka,
Karolina A. [Reprint author]

L6 ANSWER 10 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Dendritic cells capture tumor cell bodies and process/present their
antigens to elicit tumorspecific immune responses.
PY 2000
AU Palucka, Karolina [Reprint author]; Nouri-Shirazi, Mahyar [Reprint
author]; **Blanco, Patrick** [Reprint author]; Berard, Frederic
[Reprint author]; Neidhart-Berard, Eve-Marie [Reprint author];
Burkeholder, Susan [Reprint author]; Kraus, Elizabeth [Reprint author];
Davoust, Jean [Reprint author]; **Banchereau, Jacques** [Reprint

author]
SO Journal of Investigative Dermatology, (Jan., 2000) Vol. 114, No. 1, pp. 236. print.
Meeting Info.: The Sixth International Workshop on Langerhans Cells. New York, New York, USA. October 08-10, 1999.
CODEN: JIDEAE. ISSN: 0022-202X.

AU Palucka, Karolina [Reprint author]; Nouri-Shirazi, Mahyar [Reprint author]; **Blanco, Patrick** [Reprint author]; Berard, Frederic [Reprint author]; Neldhart-Berard, Eve-Marie [Reprint author]; Burkeholder, Susan [Reprint author]; Kraus, Elizabeth [Reprint author]; Davoust, Jean [Reprint author]; **Banchereau, Jacques** [Reprint author]

L6 ANSWER 11 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Dendritic cells capture breast cancer cells and present their antigens to elicit tumor-specific CD4+ and CD8+ T cells.
PY 2000
AU Neidhardt-Berard, Eve-Marie [Reprint author]; Berard, Frederic [Reprint author]; **Blanco, Patrick** [Reprint author]; Minna, John; Gazdar, Adi; **Banchereau, Jacques** [Reprint author]; Palucka, Karolina [Reprint author]
SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 2, pp. 30b-31b. print.
Meeting Info.: 42nd Annual Meeting of the American Society of Hematology. San Francisco, California, USA. December 01-05, 2000. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.

AU Neidhardt-Berard, Eve-Marie [Reprint author]; Berard, Frederic [Reprint author]; **Blanco, Patrick** [Reprint author]; Minna, John; Gazdar, Adi; **Banchereau, Jacques** [Reprint author]; Palucka, Karolina [Reprint author]

L6 ANSWER 12 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Dendritic cell subsets in pediatric Lupus patients.
PY 2000
AU Gill, Michelle A. [Reprint author]; **Blanco, Patrick**; **Banchereau, Jacques**; Pascual, Virginia; Pulendran, Bali; Palucka, Karolina
SO Pediatric Research, (April, 2000) Vol. 47, No. 4 Part 2, pp. 17A. print.
Meeting Info.: Joint Meeting of the Pediatric Academic Societies and the American Academy of Pediatrics. Boston, Massachusetts, USA. May 12-16, 2000. American Academy of Pediatrics; American Pediatric Society; Society for Pediatric Research.
CODEN: PEREBL. ISSN: 0031-3998.

AU Gill, Michelle A. [Reprint author]; **Blanco, Patrick**; **Banchereau, Jacques**; Pascual, Virginia; Pulendran, Bali; Palucka, Karolina

=> d his

(FILE 'HOME' ENTERED AT 08:51:42 ON 16 AUG 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 08:52:03 ON 16 AUG 2005

E BANCHEREAU JACQUES /AU

L1 546 S E3

E PALUCKA ANNA /AU

L2 5 S E5

L3 1 S E4

E BLANCO PARTICK /AU

L4 41 S E8

L5 18 S L1 (L) L4

L6 12 DUP REM L5 (6 DUPLICATES REMOVED)

L7 48026 S PSORIASIS

L8 38666 S AUTOIMMUNIT?

L9 123 S L7 (L) L8

L10 31779 S SLE

L11 15 S L9 (L) L10

L12 8 DUP REM L11 (7 DUPLICATES REMOVED)

L12 ANSWER 1 OF 8 MEDLINE on STN
 TI, Connective tissue disease in children.
 PY 2005
 AU Buka Robert L; Cunningham Bari B
 SO Pediatric annals, (2005 Mar) 34 (3) 225-9, 233-8. Ref: 36
 Journal code: 0356657. ISSN: 0090-4481.
 AB As our understanding of connective tissue disease expands, so too does our therapeutic armamentarium. We have learned that **autoimmunity** triggers inflammation through unchecked, proliferative cell-mediated inflammation. By targeting this arm of the cytokine cascade, it may be possible to. . . further progression. Several biologic agents, such as etanercept, alefacept, infliximab, efalizumab, and, recently, adalimumab, have come to market for adult **psoriasis** and are now undergoing trials for juvenile **SLE**, **psoriasis**, and psoriatic arthritis. Of note, etanercept has been used successfully in juvenile rheumatoid arthritis for more than 10 years. These. . .

L12 ANSWER 2 OF 8 MEDLINE on STN DUPLICATE 1
 TI Recent findings on genes associated with inflammatory disease.
 PY 2005
 AU Yamada Ryo; Ymamamoto Kazuhiko
 SO Mutation research, (2005 Jun 3) 573 (1-2) 136-51. Ref: 75
 Journal code: 0400763. ISSN: 0027-5107.
 AB . . . of medical conditions. In this chapter, autoimmune diseases and allergic disorders will be our focus. The autoimmune diseases include organ-specific **autoimmunities**, such as type I diabetes mellitus and autoimmune thyroiditis (AITD), and organ non-specific disorders such as systemic lupus erythematosus (**SLE**). All of them seem to share aspects of aberrant immunologic tolerance toward self-antigens. Asthma and atopic diathesis are among the allergies. Crohn disease and **SLE** are relatively rare with a prevalence of 10-50 per 100,000, and rheumatoid arthritis (RA), **psoriasis**, AITD and asthma are commoner with a prevalence of 500 per 100,000 or much higher. The difference among ethnic groups is not prominent for rheumatoid arthritis, **psoriasis**, AITD or asthma, but Crohn disease and **SLE** affect some ethnic populations more than others. Although all of these disorders have some environmental component, asthma and atopy seem. . .

L12 ANSWER 3 OF 8 MEDLINE on STN DUPLICATE 2
 TI Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis.
 PY 2004
 AU Huang Chun-Mei; Yang Yao-Hsu; Chiang Bor-Luen
 SO Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, (2004 Apr) 37 (2) 88-94.
 Journal code: 100956211. ISSN: 1684-1182.
 AB . . . this study was to determine if the prevalence of autoimmune disorders in the relatives of patients with systemic lupus erythematosus (**SLE**) is greater than that of relatives of patients with juvenile rheumatoid arthritis (JRA). Interviews were used to obtain histories of the following autoimmune disorders among living or deceased first-, second-, and third-degree relatives of 91 **SLE** and 110 JRA families: ankylosing spondylitis, **SLE**, rheumatoid arthritis (RA), JRA, multiple sclerosis, juvenile dermatomyositis, Sjogren's syndrome, myasthenia gravis, **psoriasis**, and thyroid diseases. There were statistically significant differences between the **SLE** and JRA probands in mean age and gender ratio (19.1 +/- 4.8 vs 14.0 +/- 5.5 years; M (male)/F (female): 17/74 vs 62/48, p<0.005). The prevalence rate of autoimmune diseases in relatives of **SLE** families (20.9%) was greater than in JRA families (11.8%), but not statistically significantly so. The mean age (18.0 +/- 5.3. . . 5/8) of the patients with affected relatives between these 2 groups all had statistically significant differences. A higher prevalence of **SLE** in relatives was found in **SLE** families than in JRA cases. Furthermore, this study revealed a higher incidence of autoimmune disorders among second- and third-degree relatives of **SLE** or JRA

probands versus first-degree ones, especially sisters (including 1 pair of twins) and the maternal aunt in **SLE** families. These data demonstrate that the prevalence of autoimmune disorders in the relatives of patients with **SLE** is greater than those of relatives of patients with JRA. This suggests that clinically different autoimmune phenotypes may share common susceptibility genes, which may act as risk factors for **autoimmunity**.

L12 ANSWER 4 OF 8 MEDLINE on STN DUPLICATE 3
TI IDEC-131. IDEC/Eisai.
PY 2002
AU Dumont Francis J
SO Current opinion in investigational drugs (London, England : 2000), (2002 May) 3 (5) 725-34. Ref: 60
Journal code: 100965718. ISSN: 1472-4472.
AB . . . IDEC licensed from Dartmouth Medical School where researchers demonstrated the biological effects of the anti-CD154 antibody in animal models of **autoimmunity**. In January 2001, phase II trials in **psoriasis** and idiopathic thrombocytopenic purpura (ITP) were initiated. By January 2002, a phase II trial in Crohn's disease was also ongoing. A pilot, multicenter, multiple-dose phase I trial in moderate-to-severe **psoriasis** was initiated in January 2001. This trial was ongoing in January 2002. IDEC, in collaboration with Dartmouth Medical School had. . . a phase I trial in multiple sclerosis by March 1999. IDEC-131 was also previously being developed for systemic lupus erythematosus (**SLE**), although no further development for this indication has been reported since the disclosure of disappointing phase II results in April. . .

L12 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
TI Novel approaches to therapy for systemic lupus erythematosus
PY 2000
AU Zandman-Goddard, Gisele; Shoenfeld, Yehuda
SO European Journal of Internal Medicine (2000), 11(3), 130-134
CODEN: EJIMEJ; ISSN: 0953-6205
AB A review with 29 refs. Current therapies for systemic lupus erythematosus (**SLE**) are targeted at immunosuppression and at reducing inflammation. The current therapies are broad-spectrum and include steroids and cytotoxic agents that. . . by toxicity and side effects of the medications. Methotrexate can be utilized to reduce steroid requirements in mild to moderate **SLE**. Manipulation of the hormonal axis includes DHEA and bromocriptine. Mycophenolate mofetil is an immunosuppressive agent that is being investigated for **SLE** renal disease. Autologous stem cell transplantation or high-dose cyclophosphamide may be an option for severe refractory **SLE**. The aim of the future is to target therapies by altering specific known mechanisms of inflammation and **autoimmunity**. Although the inciting antigen is still unknown in **SLE**, it may be possible to alter the regulation of the immune response by targeted mol. therapy. Methods to do so. . . induction of tolerance by administration of blocking peptides. IVIg is an immunomodulator that has been successful in the treatment of **SLE**. Targeted mol. therapy is undergoing phase I trials with monoclonal anti-CD40L, a signaling inhibitor. Anti-CTLA4Ig, another signaling blocker, is presently being investigated for **psoriasis**, but may be a potential therapy for **SLE**. Finally, therapies may include the administration of peptides to induce tolerance.

L12 ANSWER 6 OF 8 MEDLINE on STN DUPLICATE 4
TI Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree.
PY 1999
AU Sestak A L; Shaver T S; Moser K L; Neas B R; Harley J B
SO Journal of rheumatology, (1999 Jul) 26 (7) 1495-9.
Journal code: 7501984. ISSN: 0315-162X.
AB OBJECTIVE: To evaluate an unusual pedigree with 8 members diagnosed with systemic lupus erythematosus (**SLE**) METHODS: Pedigree members were evaluated through questionnaires, interviews, and medical records.

Sixty members contributed serum samples for autoantibody analysis.
 RESULTS: . . . nephritis (4/8). A total of 15 of 51 (29%) blood
 relatives had autoantibodies; 9 had autoimmune disease, including 7 with
SLE, one with **psoriasis**, and one with Sjogren's
 syndrome. Five of 11 (45%) nonconsanguineous spouses also had
 autoantibodies; one spouse had **SLE**, and 2 others had thyroid
 disease. Among 68 spouses of patients with **SLE** in other
 pedigrees, only 9 (13%) had autoantibodies, and none were symptomatic ($p =$
 0.02). CONCLUSION: The high rate of **autoimmunity** among both
 blood relatives and nonconsanguineous mates in this unusual pedigree
 suggests a complex interaction of genetic and environmental factors. . .

L12 ANSWER 7 OF 8 MEDLINE on STN DUPLICATE 5
 TI HLA typing in a large family with multiple cases of different autoimmune
 diseases.
 PY 1997
 AU Sels F; Westhovens R; Emonds M P; Vandermeulen E; Dequeker J
 SO Journal of rheumatology, (1997 May) 24 (5) 856-9.
 Journal code: 7501984. ISSN: 0315-162X.
 AB . . . OBJECTIVE: Because of the concurrence, in members of one family,
 of different autoimmune disorders [rheumatoid arthritis (RA), systemic
 lupus erythematosus (**SLE**), **psoriasis** (PS), and
 inflammatory bowel disease (IBD)], we investigated the genotypes of each
 member and compared the results with current knowledge. . . ad 4 of 5
 showed the maternal A2B51DR4 haplotype. Two of 3 siblings with the
 genotype HLA-A2/3, B8/35, DR2/3 had **SLE**. Patients with IBD and
psoriasis shared the haplotype HLA-A3, B35 CW4 DR2. CONCLUSION:
 The results show that the important role of patients, sex and confirm the
 association between HLA haplotype and RA or **SLE**. They support
 the hypothesis that **autoimmunity** is a mendelian dominant trait,
 and that secondary genes, including these of the major histocompatibility
 complex, confer phenotypic specificity.

L12 ANSWER 8 OF 8 MEDLINE on STN DUPLICATE 6
 TI T cell antigen receptors in autoimmunity.
 PY 1988
 AU Posnett D N; Gottlieb A; Bussel J B; Friedman S M; Chiorazzi N; Li Y;
 Szabo P; Farid N R; Robinson M A
 SO Journal of immunology (Baltimore, Md. : 1950), (1988 Sep 15) 141 (6)
 1963-9.
 Journal code: 2985117R. ISSN: 0022-1767.
 AB . . . autoimmune diseases, TCR were analyzed in different autoimmune
 diseases and control groups including rheumatoid arthritis, Graves
 disease, idiopathic thrombocytopenic purpura, **psoriasis**,
SLE, insulin-dependent diabetes mellitus, and in nonautoimmune
 control diseases and normals. Purified T cells were stained by indirect
 immunofluorescence with three. . . available mAb, could not be
 associated with any of the diseases studied. Examination of T cells at
 the site of **autoimmunity**, such as T cells from rheumatoid
 arthritis synovial fluid, revealed normal percentages of cells staining
 with these mAb. Immunoperoxidase staining. . .

=> d his

(FILE 'HOME' ENTERED AT 09:30:18 ON 16 AUG 2005)

FILE 'CAPLUS, MEDLINE, BIOSIS' ENTERED AT 09:30:33 ON 16 AUG 2005

L1 97046 S AUTOIMMUNE (1W) DISEASE
L2 201 S INTERFERON (1W) ANTAGONIST
L3 772 S INTERFERON ANTIBODY
L4 7 S L1 (L) L3
L5 4 S L1 (L) L2
L6 0 S L4 (L) L5
L7 7 DUP REM L4 (0 DUPLICATES REMOVED)
L8 4 DUP REM L5 (0 DUPLICATES REMOVED)
L9 10 S L4 OR L5
L10 7 S L9 AND TREATMENT
L11 53593 S INTERFERON WITH ALPHA
L12 7865 S L11 AND ANTIBODY
L13 152 S L12 AND AUTOIMMUNITY
L14 103 S L13 AND TREATMENT
L15 0 S L14 AND INTERFERON WITH ANTAGONIST
L16 0 S L14 AND INTERFERON (W) ANTAGONIST
L17 0 S L14 AND ANTAGOIST
L18 64 DUP REM L14 (39 DUPLICATES REMOVED)
L19 0 S L18 AND INTERFREON (1W) (ALPHA OR TYPEI)
L20 0 S L18 AND INTERFORON (1W) ALPHA
L21 53593 S L11 AND INTERFERON (1W) ALPHA
L22 55 S L18 AND PY<2003
L23 0 S L22 AND INTERFERON WITH ALPHA SAME ANTIBODY
L24 316 S INTERFERON WITH ALPHA WITH ANTIBODY
L25 30 S L24 AND AUTOIMMUNE WITH DISEASE
L26 14 S L25 AND TREATMENT
L27 14 DUP REM L26 (0 DUPLICATES REMOVED)

TI Viral **interferon antagonists** and uses therefor

PY 2003

2004

2004

SO U.S. Pat. Appl. Publ., 28 pp.

CODEN: USXXCO

IN Palese, Peter; Garcia-sastre, Adolfo

TI Viral **interferon antagonists** and uses therefor

AB The present invention relates to compns. comprising one or more viral

interferon antagonists and methods of utilizing said

compns. to modulate the cellular interferon immune response. In

particular, the present invention relates to pharmaceutical compns.

comprising one or more viral **interferon antagonists**

and methods of utilizing said compns. to prevent, treat or ameliorate an

immune disorder characterized by aberrant interferon expression and/or.

. or ameliorating the symptoms of an inflammatory disorder comprising

administering to a subject in need thereof one or more viral

interferon antagonist. The present invention also

relates to compns. comprising fusion proteins comprising one or more viral

interferon antagonists and a heterologous polypeptide,

and methods of using said compns. to modulate the cellular interferon

immune response. The present invention further relates to articles of

manufacture comprising one or more viral **interferon**

antagonists or fusion proteins.

ST viral **interferon antagonist** fusion protein

antiinflammatory

IT Inflammation

(Crohn's disease; viral **interferon antagonists** and

uses therefor)

IT Intestine, disease

(Crohn's; viral **interferon antagonists** and uses

therefor)

IT Influenza A virus

(NS1; viral **interferon antagonists** and uses

therefor)

IT Respiratory syncytial virus

(NS2; viral **interferon antagonists** and uses

therefor)

IT Ebola virus

(VP35; viral **interferon antagonists** and uses

therefor)

IT **Interferons**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**antagonists**; viral **interferon antagonists**

and uses therefor)

IT **Autoimmune** disease

Inflammation

Thyroid gland, disease

(**autoimmune** thyroiditis; viral **interferon**

antagonists and uses therefor)

IT Dermatitis

(contact; viral **interferon antagonists** and uses

therefor)

IT Transplant and Transplantation

(graft-vs.-host reaction; viral **interferon**

antagonists and uses therefor)

IT T cell (lymphocyte)

(helper cell/inducer, TH1; viral **interferon**

antagonists and uses therefor)

IT Anti-inflammatory agents

Antiarthritics

Arthritis

Diabetes mellitus

Drug delivery systems

Graves' disease

Human

Immunosuppressants
Lyme disease
Multiple sclerosis
 Psoriasis
Sarcoidosis
Transplant rejection
 (viral interferon antagonists and uses therefor)

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
TI Antagonist of Th1 immune response inducing cytokine for the treatment of
 autoimmune diseases
PY 2001
 2001
 2002
 2003
 2003
SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
IN Tovey, Michael Gerard
TI Antagonist of Th1 immune response inducing cytokine for the treatment of
 autoimmune diseases
AB . . . of T helper 1 cell responses, preferably for example a Type
 1-interferon antibody, is disclosed for inhibition of prevention of
 autoimmune diseases.
ST **autoimmune** disease therapy Th1 cytokine antagonist; interferon
 antibody **autoimmune** disease therapy
IT Immunoglobulins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (G; antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT **Autoimmune** disease
 Multiple sclerosis
 Psoriasis
 Rheumatoid arthritis
 (antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Cytokines
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Antibodies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT T cell (lymphocyte)
 (helper cell/inducer, TH1; antagonists of Th1 cell-inducing cytokine
 for treatment of **autoimmune** diseases)
IT Diabetes mellitus
 (insulin-dependent; antagonists of Th1 cell-inducing cytokine for
 treatment of **autoimmune** diseases)
IT Antibodies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (monoclonal; antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Drug delivery systems
 (nasal; antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Drug delivery systems
 (oral; antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Cytokine receptors
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(soluble; antagonists of Th1 cell-inducing cytokine for treatment of **autoimmune** diseases)

IT Lupus erythematosus
(systemic; antagonists of Th1 cell-inducing cytokine for treatment of **autoimmune** diseases)

IT Interferon receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(α/β - **interferon**; antagonists of Th1 cell-inducing cytokine for treatment of **autoimmune** diseases)

IT Interferons
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(α/β ; antagonists of Th1 cell-inducing cytokine for treatment of **autoimmune** diseases)

IT **Interferons**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(α ; **antagonists** of Th1 cell-inducing cytokine for treatment of **autoimmune** diseases)

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

TI Methods and compositions for modulating responsiveness to corticosteroids

PY 1998
2000
2000
1998
1998
2001
2000
2000
2000
2002
2002
1999

SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

IN Sekut, Les; Carter, Adam; Chayur, Tariq; Banerjee, Subhashis; Tracey, Daniel E.

IT Thyroid gland, disease
(**autoimmune** thyroiditis; methods and compns. for modulating responsiveness to corticosteroids in the treatment of a variety of inflammatory and immunol. diseases and disorders)

IT Eye, disease
Eye, disease
(**autoimmune** uveitis; methods and compns. for modulating responsiveness to corticosteroids by co-administration of another agent)

IT Arthritis
Encephalomyelitis
Meningitis
(**autoimmune**; methods and compns. for modulating responsiveness to corticosteroids by co-administration of another agent)

IT Antiasthmatics
Antirheumatic agents
Autoimmune disease
Dermatitis
Drug allergy
Eczema
Multiple sclerosis
Psoriasis
Sjogren's syndrome
Transplant rejection
(methods and compns. for modulating responsiveness to corticosteroids in the treatment of a variety of inflammatory and immunol. diseases and disorders)

IT **Interferons**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES / (Uses)
(γ, antagonists; methods and compns. for modulating responsiveness to corticosteroids by co-administration of another agent)

=> d his ful .

(FILE 'HOME' ENTERED AT 17:01:07 ON 05 AUG 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 17:01:33 ON 05 AUG 2005

L1	201	SEA	ABB=ON	PLU=ON	INTERFERON (1W) ANTAGONIST
L2	3	SEA	ABB=ON	PLU=ON	L1 AND PSORIASIS
L3	11	SEA	ABB=ON	PLU=ON	L1 AND AUTOIMMUNE?
L4	11	DUP	REM	L3	(0 DUPLICATES REMOVED)
L5	3	SEA	ABB=ON	PLU=ON	L4 AND PSORIASIS

- L17 ANSWER 1 OF 9 MEDLINE on STN
 TI Connective tissue disease in children.
 AU Buka Robert L; Cunningham Bari B
 SO Pediatric annals, (2005 Mar) 34 (3) 225-9, 233-8. Ref: 36
 Journal code: 0356657. ISSN: 0090-4481.
- L17 ANSWER 2 OF 9 MEDLINE on STN DUPLICATE 1
 TI Recent findings on genes associated with inflammatory disease.
 AU Yamada Ryo; Ymamoto Kazuhiko
 SO Mutation research, (2005 Jun 3) 573 (1-2) 136-51. Ref: 75
 Journal code: 0400763. ISSN: 0027-5107.
- L17 ANSWER 3 OF 9 MEDLINE on STN DUPLICATE 2
 TI Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis.
 AU Huang Chun-Mei; Yang Yao-Hsu; Chiang Bor-Luen
 SO Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, (2004 Apr) 37 (2) 88-94.
 Journal code: 100956211. ISSN: 1684-1182.
- L17 ANSWER 4 OF 9 MEDLINE on STN DUPLICATE 3
 TI IDEC-131. IDEC/Eisai.
 AU Dumont Francis J
 SO Current opinion in investigational drugs (London, England : 2000), (2002 May) 3 (5) 725-34. Ref: 60
 Journal code: 100965718. ISSN: 1472-4472.
- L17 ANSWER 5 OF 9 MEDLINE on STN
 TI Antinuclear autoantibodies in flaky skin (fsn) mutant mice.
 AU Withington Susan; Maltby-Askari Ellen; Welner Robert; Parker Russ; Pelsue Stephen C
 SO Autoimmunity, (2002 May) 35 (3) 175-81.
 Journal code: 8900070. ISSN: 0891-6934.
- L17 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 TI Novel approaches to therapy for systemic lupus erythematosus
 AU Zandman-Goddard, Gisele; Shoenfeld, Yehuda
 SO European Journal of Internal Medicine (2000), 11(3), 130-134
 CODEN: EJIMEJ; ISSN: 0953-6205
- L17 ANSWER 7 OF 9 MEDLINE on STN DUPLICATE 4
 TI Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree.
 AU Sestak A L; Shaver T S; Moser K L; Neas B R; Harley J B
 SO Journal of rheumatology, (1999 Jul) 26 (7) 1495-9.
 Journal code: 7501984. ISSN: 0315-162X.
- L17 ANSWER 8 OF 9 MEDLINE on STN DUPLICATE 5
 TI HLA typing in a large family with multiple cases of different autoimmune diseases.
 AU Sels F; Westhovens R; Emonds M P; Vandermeulen E; Dequeker J
 SO Journal of rheumatology, (1997 May) 24 (5) 856-9.
 Journal code: 7501984. ISSN: 0315-162X.
- L17 ANSWER 9 OF 9 MEDLINE on STN DUPLICATE 6
 TI T cell antigen receptors in autoimmunity.
 AU Posnett D N; Gottlieb A; Bussel J B; Friedman S M; Chiorazzi N; Li Y; Szabo P; Farid N R; Robinson M A
 SO Journal of immunology (Baltimore, Md. : 1950), (1988 Sep 15) 141 (6) 1963-9.
 Journal code: 2985117R. ISSN: 0022-1767.

=> d his

(FILE 'HOME' ENTERED AT 08:51:42 ON 16 AUG 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 08:52:03 ON 16 AUG 2005

E BANCHEREAU JACQUES /AU

L1	546 S E3
	E PALUCKA ANNA /AU
L2	5 S E5
L3	1 S E4
	E BLANCO PARTICK /AU
L4	41 S E8
L5	18 S L1 (L) L4
L6	12 DUP REM L5 (6 DUPLICATES REMOVED)
L7	48026 S PSORIASIS
L8	38666 S AUTOIMMUNIT?
L9	123 S L7 (L) L8
L10	31779 S SLE
L11	15 S L9 (L) L10
L12	8 DUP REM L11 (7 DUPLICATES REMOVED)
L13	49 S L9 AND TREATMENT
L14	38 DUP REM L13 (11 DUPLICATES REMOVED)
L15	992 S L10 (L) L8
L16	16 S L15 AND L7
L17	9 DUP REM L16 (7 DUPLICATES REMOVED)